Symbiotec Pharmalab Ltd. Share Price

Nifty Fails at Resistance; Pre-Market Bias Weak

It was a volatile session yesterday, with Nifty initially moving higher and testing the 22,777 falling-window resistance flagged earlier. A sharp sell-off followed, erasing all the gains and pushing the index into negative territory, closing near the 22,600 support. This points to supply emerging at higher levels, with the index unable to sustain strength once it approached resistance. RSI at 36.02 has eased back after the failed push higher, reflecting the renewed selling pressure that capped the session's gains. Resistance: 22,700-22,650 cluster, then 22,750 and 22,890. Support: 22,540, then 22,460. The 22,700-22,650 resistance cluster points toward a weaker opening for the day. On the downside, 22,540 is the initial level sellers may target, with 22,460 as the extreme level below that. A move above 22,700 could open the path toward 22,750 and 22,890, though current cues suggest a broad range with a sideways-to-lower bias is more likely for the day.

is hovering near a level that has acted as a near-triple top on the chart, with price struggling to move decisively past it on recent attempts. It's worth noting the stock listed only in September, so this price history is still fairly limited and the usual weight given to a multi-touch resistance may not fully apply here. RSI at 78.39 is elevated, and whether the stock can finally clear this zone or continues to be capped by it is something to watch over the next few sessions. A resistance pattern carries more weight when it has formed over a longer price history — a newly listed stock's early chart patterns deserve a more cautious read. Disclaimer:This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More

Symbiotec Pharmalab posts 7% revenue growth, profit halves

Symbiotec Pharmalab Limited [

] reported a 7 percent year-on-year growth in consolidated revenue for Q1 FY27. Net profit nearly halved during the quarter due to rising operational expenses and higher depreciation linked to new growth initiatives. The sharp drop in net profit reflects execution costs rather than weakness in core operations. While gross margins expanded to 65 percent from 62 percent in Q1 FY26, EBITDA margins compressed to 21 percent from 28 percent. The company is actively investing in double chamber technology for complex injectables and expanding its bio-CDMO capacity. Headline profit numbers mask the structural transition underway. Over 56 percent of the company's total capex of Rs 1,475 crore is allocated to new growth engines, which are yet to generate full revenue. Commercialisation of key double-chamber vial products and long-term take-or-pay agreements in the CDMO space offer strong revenue visibility. With legacy API facilities operating at high capacity and the stock trading at a valuation discount to peers like Concord Biotech and Laurus Labs, the margin pressure appears temporary. Investors should track the commercial execution of double-chamber vial products scheduled for FY28, regulatory approvals in the US market, and margin recovery over the next two to four quarters. For long-term investors, accumulating the stock on dips presents a favorable risk-reward opportunity.

See More

Symbiotec Pharmalab: FY27 Strategic & Financial Update

Executive Summary Symbiotec Pharmalab projects a robust 20-25% consolidated growth in revenue and EBITDA for FY27. While Q1FY27 experienced a temporary growth moderation to 7.4% due to planned OpEx and depreciation from recent strategic investments, the company's core fundamentals remain highly resilient. Core Operations & H2 Catalysts The foundational Active Pharmaceutical Ingredient (API) segment—representing over 90% of total revenue—continues to deliver consistent high single-digit growth while sustaining strong EBITDA margins near 30%. Management anticipates multi-million-dollar commercial milestones in H2 FY27. These major capital inflows are projected to offset early margin compressions, ensuring the company meets its targeted annual growth trajectory. Biotechnology Expansion (CDMO/CMO) A pivotal growth engine is the newly established biotechnology CDMO and CMO vertical, backed by a ₹400 crore CapEx in large-scale, fermentation-led synthetic biology facilities. The investment's gestation period is concluding, with initial revenue generation slated for Q4 FY27 before a significant scale-up next year. Margin Profile: The biotech vertical is positioned to achieve industry-leading gross margins exceeding 70% and EBITDA margins above 35%. Revenue Forecast: Operating with an expected asset turnover ratio greater than 1.0x, this CapEx is projected to generate ₹300-400 crore in revenue over the next three years. Regulatory Compliance Symbiotec maintains a stringent compliance posture. The company recently underwent four major USFDA audits across its Rau and Pithampur facilities, successfully clearing three with Establishment Inspection Reports (EIR). A final audit at Pithampur resulted in four purely procedural observations. Management is highly confident in receiving the corresponding EIR within the next 2-3 months.

See More

Symbiotec Pharmalab Reports Q1 FY27 Financial Results

Symbiotec Pharmalab reported Q1 FY27 revenue of ₹218.2 crore, compared with ₹203.2 crore in Q1 FY26, marking a 7.4% YoY increase. Profitability Performance: On a standalone basis, net profit increased to ₹47.0 crore from ₹44.5 crore, while revenue stood at around ₹210.8 crore. However, on a consolidated basis, EBITDA declined to ₹45.2 crore from ₹58.0 crore, while EBITDA margin moderated to approximately 21% from 29%. Consolidated PAT stood at ₹14.1 crore versus ₹29.9 crore in the corresponding quarter last year. The decline was attributed to expenses associated with new business initiatives that have not yet started generating commercial revenue. API Business Continues to Grow The core API business reported operating revenue of ₹215.3 crore, compared with ₹203.2 crore a year ago. API EBITDA increased to ₹65.8 crore from ₹60.1 crore, with EBITDA margins of around 30%. Expansion Across New Businesses Symbiotec is investing in complex injectables, biotech CDMO services and biopharmaceuticals. The company expects commercial revenue from several new capacities to begin over the next 6–12 months. During the quarter, the company also submitted its first ANDA filing for a Dual Chamber Vial product in the US, while additional filings are planned. The company estimates gross capital expenditure of approximately ₹1,666 crore by the end of FY27, supporting its expansion across these new business verticals. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their risk profile before making any investment decision.

See More